Advances in the formulations of non-injection administration of docetaxel

References

• Walker RA, Jones JL, Chappell S, et al. Molecular pathology of breast cancer and its application to clinical management. Cancer Metast Rev 1997;16:5–27
   PubMed Web of Science ®Google Scholar
• Figgitt DP, Wiseman LR. Docetaxel. Drugs 2000;59:621–51
   PubMed Web of Science ®Google Scholar
• Kaye SB. The integration of docetaxel into first-line chemotherapy for ovarian cancer. Int J Gynecol Cancer 2001;11:31–3
   PubMed Web of Science ®Google Scholar
• Belani CP, Eckardt J. Development of docetaxel in advanced non- small-cell lung cancer. Lung Canc 2004;46:3–11
   Google Scholar
• Petrylak DP. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol 2000;27:24–9
   PubMed Web of Science ®Google Scholar
• Ridwelski K, Gebauer T, Fahlke J, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001;12:47–51
   PubMed Web of Science ®Google Scholar
• Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995;22:3–16
   Web of Science ®Google Scholar
• Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643–55
   PubMed Web of Science ®Google Scholar
• Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747–55
   PubMed Web of Science ®Google Scholar
• Riou JF, Petitgenet O, Combeau C, Lavelle F. Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line. Proc Am Assoc Cancer Res 1994;35:385
   Google Scholar
• Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229–33
   PubMed Web of Science ®Google Scholar
• Haas H. Development of new taxane formulations. Pharm Unserer Zeit 2005;34:115–21
   PubMedGoogle Scholar
• Baker J, Ajani J, Scotte F, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009;13:49–59
   PubMed Web of Science ®Google Scholar
• Feng SS, Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 2003;58:4087–114
   Web of Science ®Google Scholar
• Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 2007;64:4–7
   PubMed Web of Science ®Google Scholar
• Gao K, Sun J, Liu K, et al. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm 2008;34:1227–37
   PubMed Web of Science ®Google Scholar
• Park K. Nanovehicles for enhanced oral delivery of taxanes. J Contr Rel 2009;140:77–8
   PubMed Web of Science ®Google Scholar
• Waterschoot RA, Lagas JS, Wagenaar E, et al. Absence of both cytochromeP4503A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. J Cancer Res Clin 2009;69:8996–9002
   Google Scholar
• Sun P, Zhang Y, Shi L, Gan Z. Thermosensitive nanoparticles self-assembled from PCL-b-PEO-b-PNIPAAm triblock copolymers and their potential for controlled drug release. Macromol Biosci 2010;10:621–31
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998;95:4607–12
   PubMed Web of Science ®Google Scholar
• Sanders E, Ashworth CT. A study of particulate intestinal absorption and hepatocellular uptake. Exp Cell Res 1961;22:137–45
   PubMed Web of Science ®Google Scholar
• Florence AT, Hillery AM, Hussain N, Jani PU. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Release 1995;36:39–46
   Web of Science ®Google Scholar
• Lefevre ME, Vanderhoff JW, Laussue JA, Joel DD. Accumulation of 2-mm latex particles in mouse Peyer's patches during chronic latex feeding. Cell Mol Life Sci 1978;34:120–2
   Google Scholar
• Jung T, Kamm W, Breitenbach A, et al. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm 2000;50:147–60
   PubMed Web of Science ®Google Scholar
• Delie F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv Drug Del Rev 1998;34:221–33
   PubMed Web of Science ®Google Scholar
• Mu L, Feng SS. A novel controlled release formulation for anticancer drug paclitaxel (Taxols): PLGA nanoparticles containing vitamin E TPGS. J Contr Rel 2003;86:33–48
   PubMed Web of Science ®Google Scholar
• Mu L, Feng SS. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and the drug loading ratio. Pharm Res 2003;20:1864–72
   PubMed Web of Science ®Google Scholar
• Feng SS, Mei L, Anitha P, et al. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 2009;30:3297–306
   PubMed Web of Science ®Google Scholar
• Lee YH, Kuo TF, Chen BY, et al. Toxicity assessment of montmorillonite as a drug carrier for pharmaceutical applications: yeast and rats model. Biomed Eng-App Bas C 2005;17:12–18
   Google Scholar
• Norris DA, Puri N, Sinko PJ. The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Del Rev 1998;34:135–54
   PubMed Web of Science ®Google Scholar
• Kawakami K, Yoshikawa T, Moroto Y, et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs prescription design. J Control Rel 2002;81:65–74
   PubMed Web of Science ®Google Scholar
• Araya H, Tomita M, Hayashi M. The novel formulation design of O/W microemulsion for improving the gastrointestinal absorption of poorly water soluble compounds. Int J Pharm 2005;305:61–74
   PubMed Web of Science ®Google Scholar
• Kawakami K, Yoshikawa T, Hayashi H, et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs II. In vivo study. J Contr Rel 2002;81:75–82
   PubMed Web of Science ®Google Scholar
• Shah NH, Carvajal MT, Patel CI, et al. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 1994;106:15–23
   Web of Science ®Google Scholar
• Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res 1995;12:156–72
   Google Scholar
• Yin YM, Cui FD, Mu CF, et al. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Contr Rel 2009;140:86–94
   PubMed Web of Science ®Google Scholar
• Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47–60
   PubMed Web of Science ®Google Scholar
• Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999;88:1058–66
   PubMed Web of Science ®Google Scholar
• Moes JJ, Koolen SLW, Huitema ADR, et al. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). Int J Pharm 2011;420:244–50
   PubMed Web of Science ®Google Scholar
• Kruijtzer CM, Beijnen JH, Schellens JH. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or Cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 2002;7:516–30
   PubMed Web of Science ®Google Scholar
• Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Del Rev 2010;62:3–11
   PubMed Web of Science ®Google Scholar
• Lee E, Kim H, Lee IH, Jon S. In vivo antitumor effects of chitosan- conjugated docetaxel after oral administration. J Contr Rel 2009;140:79–85
   PubMed Web of Science ®Google Scholar
• Khatun Z, Nurunnabi M, Reeck GR, et al. Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy. J Control Release 2013;170:74–82
   PubMed Web of Science ®Google Scholar
• Park K, Lee GY, Kim YS, et al. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Contr Rel 2006;114:300–6
   PubMed Web of Science ®Google Scholar
• Kim SK, Lee DY, Lee E, et al. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. J Control Release 2007;120:4–10
   PubMed Web of Science ®Google Scholar
• Nurunnabi M, Khatun Z, Moon WC, et al. Heparin based nanoparticles for cancer targeting and noninvasive imaging. Quant Imaging Med Surg 2012;2:219–26
   Google Scholar
• Nassar T, Qadri SA, Frenkel OH, et al. High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation. Cancer Res 2011;71:3018–28
   PubMed Web of Science ®Google Scholar
• Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin’s barrier function. Pharm Sci Technolo Today 2000;3:318–26
   PubMedGoogle Scholar
• Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int J Pharm 2007;332:1–16
   PubMed Web of Science ®Google Scholar
• Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta 1992;1104:226–32
   PubMed Web of Science ®Google Scholar
• Mishra D, Garg M, Dubey V, et al. Elastic liposomes mediated transdermal delivery of an anti-hypertensive agent: propranolol hydrochloride. J Pharm Sci 2007;96:145–55
   PubMed Web of Science ®Google Scholar
• Qiu YQ, Gao YH, Hu KJ, Li F. Enhancement of skin permeation of docetaxel: a novel approach combining microneedle and elastic liposomes. J Contr Rel 2008;129:144–50
   PubMed Web of Science ®Google Scholar
• Qiu YQ, Li S, Li F, et al. Enhancement of transdermal delivery of docetaxel by surfactantethanolic liposomes. J Chin Pharm Sci 2011;20:466–72
   Google Scholar
• Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Int J Nanomed 2008;3:761–76
   Web of Science ®Google Scholar
• Timothy M, Crowder TM, Rosati JA, et al. Fundamental effects of particle morphology on lung delivery: predictions of Stokes’ Law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 2000;19:239–45
   Web of Science ®Google Scholar
• Telko MJ, Hickey AJ. Dry powder inhaler formulation. Resp Care 2005;50:1209–27
   PubMedGoogle Scholar
• Islam N, Gladki E. Dry powder inhalers (DPIs) -- a review of device reliability and innovation. Int J Pharm 2008;360:1–11
   PubMed Web of Science ®Google Scholar
• Jinturkar KA, Anish C, Kumar MK, et al. Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials 2012;33:2492–507
   PubMed Web of Science ®Google Scholar
• Chiang LM, Wang HS, Shen HH, et al. Rectal diazepam solution is as good as rectal administration of intravenous diazepam in the first-aid cessation of seizures in children with intractable epilepsy. Pediatr Neonatol 2011;52:30–3
   PubMed Web of Science ®Google Scholar
• Hoogdalem E, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration, Part I. Clin Pharmacokinet 1991;21:11–26
   PubMed Web of Science ®Google Scholar
• Yuan Y, Cui Y, Zhang L, et al. Thermosensitive and mucoadhesive in situ gel based on poloxamer as new carrier for rectal administration of nimesulide. Int J Pharm 2012;430:114–19
   PubMed Web of Science ®Google Scholar
• Choi HG, Yong CS, Yeo WH. Docetaxel-loaded thermosensitive liquid suppository composition for rectal administration. WIPO, 2011. Available from: http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2011129627&recNum=191&docAn=KR2011002662&queryString=evaporators&maxRec=179088 [last accessed 20 Oct 2011]
   Google Scholar